Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2120-2127

  Lee, Min Goo ^a   Jeong, Myung Ho ^a   Ahn, Youngkeun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a   Chae, Shung Chull ^b   Hur, Seung Ho ^c   Hong, Taek Jong ^d   Kim, Young Jo ^e   Seong, In Whan ^f   Chae, Jei Keon ^g   Rhew, Jay Young ^h   Chae, In Ho ⁱ   Cho, Myeong Chan ^j   Bae, Jang Ho ^k   Rha, Seung Woon ^l   Kim, Chong Jin ^m   Choi, Donghoon ⁿ   Jang, Yang Soo ⁿ   Yoon, Junghan ^o   Chung, Wook Sung ^p   Seung, Ki Bae ^p   Park, Seung Jung ^q   more..

^a Chonnam National University Medical School   (South Korea)

^b Kyungpook National University   (South Korea)

^c Dongsan Medical Center   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

^e Young Nam University Hospital   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h Jeonju Presbyterian Medical Center   (South Korea)

ⁱ Seoul National University Bundang Hospital   (South Korea)

^j Chungbuk National University Hospital   (South Korea)

^k Konyang University College of Medicine   (South Korea)

^l Korea University College of Medicine   (South Korea)

^m Kyung Hee University College of Medicine   (South Korea)

ⁿ Yonsei University   (South Korea)

^o Wonju Severance Christian Hospital   (South Korea)

^p The Catholic University of Korea   (South Korea)

^q Asan Medical Center   (South Korea)

more..

Author keywords

Drug eluting stent; Metabolic syndrome; Myocardial infarction

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE DISEASE; ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; REPUBLIC OF KOREA; SIROLIMUS; SURVIVAL RATE;

EID: 80052157400     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0263     Document Type: Article

References (33)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
2. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark T. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: A meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-301.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al; the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
4. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
5. Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
6. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, et al; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
7. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stents. J Interv Cardiol 2006; 19: 405-413.
8. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, et al; the ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: Clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007; 100(Suppl): 45M-55M.
9. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al; the ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447.
10. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ, et al; the ENDEAVOR I Investigators. Four-year clinical followup after implantation of the Endeavor zotarolimus-eluting stents: ENDEAVOR I, the first-in-human study. Am J Cardiol 2007; 100(Suppl 8B): 56M-61M.
11. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, et al; the Women's Ischemic Syndrome Evaluation. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the Women's Ischemic Syndrome Evaluation. Circulation 2004; 109: 714-721.
12. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25: 1790-1794.
13. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.
14. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, et al; Korea Acute Myocardial infarction Registry Investigators. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
15. Sim DS, Jeong MH, Ahn YK, Kim YJ, Chae SC, Hong TJ, et al; Korea Acute Myocardial Infarction Registry Investigators. Safety and benefit of early elective percutaneous coronary intervention after successful thrombolytic therapy for acute myocardial infarction. Am J Cardiol 2009; 103: 1333-1338.
16. French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart 2004; 90: 99-106.
17. Kini AS. Coronary angiography, lesion classification and severity assessment. Cardiol Clin 2006; 24: 153-162.
18. Maginas A, Gatzov P, Chasikidis C, Voudris V, Pavlides G, Cokkinos DV. Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Am J Cardiol 1999; 83: 1562-1565.
19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752.
21. Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, et al; the GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277-283.
22. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al; the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
23. Steg G. DES fall from GRACE in STEMI: Patients face more than fourfold higher risk of death than bare-metal stent treated patients. Heart-wire. http://www.medscape.com (accessed 29 January, 2008).
24. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-1113.
25. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, et al; the TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
26. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drugeluting stents versus bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713.
27. Nakagawa Y. What is the effectiveness of drug-eluting stents in the treatment of ST-elevation myocardial infarction?: Should drug-eluting stents be indicated for patients with acute coronary syndrome? (Pro) Circ J 2010; 74: 2225-2231.
28. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al; the HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
29. Park KW, Kang SH, Chung WY, Lee HY, Park JS, Kang HJ, et al. 'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. Circ J 2010; 74: 1111-1120.
30. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100(Suppl): 36M-44M.
31. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbæk H, Tilsted HH, et al; the SORT OUT III study group. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): A randomized controlled superiority trial. Lancet 2010; 375: 1090-1099.
32. Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, et al; ZoMaxx I investigators. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimusversus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: The ZoMaxx I trial. J Am Coll Cardiol Interv 2008; 1: 524-532.
33. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.